Vitamin D analogs for obesity prevention and treatment
First Claim
1. A method for inhibiting adipocyte differentiation, inhibiting SCD-1 gene transcription, and/or reducing body fat in an animal subject in need thereof, comprising administering to the animal subject, an effective amount of a 19-nor vitamin D compound or a pharmaceutical composition comprising the compound, wherein the compound administered to the subject inhibits adipocyte differentiation, inhibits SCD-1 gene transcription, and/or reduces body fat in the animal subject, and further wherein the compound is selected from a compound of formula IID, a compound of formula IIE, a compound of formula IIF, a compound of formula IIG, a compound of formula IIH, a compound of formula IIJ, a compound of formula IIK, a compound of formula IIL, a compound of formula IIM, a compound of formula IIN, a compound of formula IIO, a compound of formula IIP, a compound of formula IIQ,
1 Assignment
0 Petitions
Accused Products
Abstract
Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α,25-dihydroxyvitamin D2 or a pharmaceutical composition that includes such an analog to a subject in need thereof. The analog may be a 19-nor vitamin D analog such as a compound of formula IA, a compound of formula IB, or a mixture thereof where the variables R1, R2, and R3 have the values described herein.
-
Citations
14 Claims
- 1. A method for inhibiting adipocyte differentiation, inhibiting SCD-1 gene transcription, and/or reducing body fat in an animal subject in need thereof, comprising administering to the animal subject, an effective amount of a 19-nor vitamin D compound or a pharmaceutical composition comprising the compound, wherein the compound administered to the subject inhibits adipocyte differentiation, inhibits SCD-1 gene transcription, and/or reduces body fat in the animal subject, and further wherein the compound is selected from a compound of formula IID, a compound of formula IIE, a compound of formula IIF, a compound of formula IIG, a compound of formula IIH, a compound of formula IIJ, a compound of formula IIK, a compound of formula IIL, a compound of formula IIM, a compound of formula IIN, a compound of formula IIO, a compound of formula IIP, a compound of formula IIQ,
Specification
-
- Resources
-
Current AssigneeWisconsin Alumni Research Foundation (University of Wisconsin System)
-
Original AssigneeWisconsin Alumni Research Foundation (University of Wisconsin System)
-
InventorsClagett-Dame, Margaret, DeLuca, Hector F., Ahrens, Jamie M., Ntambi, James M., Thomson, Brian
-
Primary Examiner(s)QAZI, SABIHA NAIM
-
Application NumberUS10/997,698Publication NumberTime in Patent Office2,743 DaysField of Search514/167, 552/653US Class Current514/167CPC Class CodesA61K 31/59 Compounds containing 9, 10-...A61K 31/592 9,10-Secoergostane derivati...A61K 31/593 9,10-Secocholestane derivat...A61P 1/16 for liver or gallbladder di...A61P 11/00 Drugs for disorders of the ...A61P 19/02 for joint disorders, e.g. a...A61P 3/02 Nutrients, e.g. vitamins, m...A61P 3/04 Anorexiants; Antiobesity ag...A61P 3/06 AntihyperlipidemicsA61P 3/10 for hyperglycaemia, e.g. an...A61P 35/00 Antineoplastic agentsA61P 43/00 Drugs for specific purposes...A61P 9/10 for treating ischaemic or a...A61P 9/12 Antihypertensives
